HR 6509119th CongressIn Committee

SAFE Drugs Act of 2025

Standard Summary
Balanced plain-English summary

The SAFE Drugs Act of 2025 would amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities. It sets limits and definitions for compounded drugs that are essentially copies of commercially available products, adds reporting requirements for certain out-of-state compounding, requires inspections of large-scale outsourcing facilities, and adjusts establishment fees.

Key Points

  • 1Limits compounding of drugs that are essentially copies of commercially available products to no more than 20 times per month.
  • 2Requires pharmacies, facilities, or physicians compounding certain drugs for out-of-state patients more than 20 times per month to report to the Secretary.
  • 3Requires pre-compounding inspections and biennial reinspections for large-scale outsourcing facilities.
  • 4Removes a registration exemption for outsourcing facilities and changes the base establishment fee.
  • 5Applies new inspection and registration requirements beginning six months after enactment.

Impact Areas

Compounding pharmaciesOutsourcing facilitiesPhysiciansPatients receiving compounded drugsFood and Drug Administration
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026